Month: May 2023

TORONTO, May 25, 2023 (GLOBE NEWSWIRE) — As announced on January 26, 2023, Acerus Pharmaceuticals Corporation (the “Company” or “Acerus”) and its subsidiaries were granted creditor protection pursuant to an order (the “Initial Order”) granted by the Ontario Superior Court of Justice (Commercial List) (the “Court”) under the Companies’ Creditors Arrangement Act (the “CCAA”). Pursuant to the Initial Order, Ernst & Young Inc. was appointed as monitor of the Company (in such capacity, the “Monitor”). As announced on March 14, 2023, the Court granted an order (the “SISP Order”) authorizing the Monitor to conduct, with the assistance of the Company, a sale and investment solicitation process (the “SISP”) intended to solicit interest in the opportunity for a sale of or investment in all or part of Acerus’ assets and business operations....

VANCOUVER, BC, CANADA, May 25, 2023 (GLOBE NEWSWIRE) — Jolt Health Inc. (formerly Love Pharma Inc.) (“Jolt” and or “the Company”) (CSE:JOLT) (FSE: G1Q0)  is pleased to announce that pursuant to a 10% interest bearing convertible debenture issued on October 12, 2022, the Issuer issued a total of 13,765,763 common shares, at $0.015 per common share in satisfaction of the aggregate interest payment owed by the Issuer of $195,000 to a Debenture holder  In addition, pursuant to Promissory Notes dated January 23, 2020 and extended to December 31, 2023, the Issuer issued a total of 6,116,913 common shares at $0.15 per common share in satisfaction of the aggregate per annum interest rate of 5% owing on the Promissory Notes.  The common shares are being issued to arms-length parties, and are subject to a four month hold period. The shares...

BRISBANE, Calif., May 25, 2023 (GLOBE NEWSWIRE) — In a release issued under the same headline earlier today by Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), please note that in the second paragraph of the release and just below it, the oral session timing has changed. The corrected release follows: New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Conference call and webcast scheduled on Sunday, June 4, 2023 at 6:00 p.m. CT Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the publication of three abstracts on the American Society of Clinical Oncology (ASCO) website. Dr. Lindsay Kilburn of Children’s National Hospital...

— Prescription Drug User Fee Act (PDUFA) Target Action Date set for November 30, 2023 — — NDA includes results from the Phase III FRESCO-2 and FRESCO clinical trials — OSAKA, Japan and CAMBRIDGE, Mass. and HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 25, 2023 (GLOBE NEWSWIRE) — Takeda (TSE:4502/NYSE:TAK) and HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted priority review of the New Drug Application (“NDA”) for fruquintinib, a highly selective and potent inhibitor of vascular endothelial growth factor receptors (“VEGFR”) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (“CRC”). If approved, fruquintinib will be the first and only highly selective inhibitor of all three...

SURREY, British Columbia, May 25, 2023 (GLOBE NEWSWIRE) — RecycLiCo Battery Materials Inc. (“RecycLiCo” or “Company”), a battery materials company that focuses on developing novel and environmentally friendly lithium-ion battery recycling and upcycling technologies, is pleased to announce the appointment of Dr. Yi Hyon Paik to its esteemed advisory board. Dr. Paik, a renowned industry expert, brings a wealth of knowledge and experience in multinational companies, the electronic materials industry, and the energy storage sector. With a distinguished career spanning several decades, Dr. Paik has held significant leadership positions in renowned organizations. He currently serves as a Senior Advisor at Ace Equity Partners, a position he has held since 2020. Previously, he was President and Chief Strategy Officer of Samsung SDI Company,...

SANTIAGO, Chile, May 25, 2023 (GLOBE NEWSWIRE) — BANCO ITAÚ CHILE (NYSE: ITCL; SSE: ITAUCL) As announced by the Bank through a notice published on May 5 in the electronic newspaper www.latercera.com –by which it was informed in detail about the exchange process of the new Bank’s shares among its shareholders with respect to the Reverse Stock Split, which will begin next May 26–, it is communicated that the amount that will be paid in cash by the Bank to the shareholders who at midnight on May 25, 2023 are holders of a total amount of shares higher than 4,500 and other than an multiple of 4,500, as compensation for each of those old shares that, because they represent a fraction of the new shares, do not qualify for the exchange, amounts to $1.862 per share, value that corresponds to the closing price of the market transactions...

NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended March 31, 2023. OPERATIONAL HIGHLIGHTS Remestemcel-L BLA filing accepted by FDA, PDUFA goal date set US Food and Drug Administration (FDA) accepted Mesoblast’s filing of the Biologics License Application (BLA) for remestemcel-L in the treatment of children with steroid-refractory graft versus host disease (SR-aGVHD) as being complete and has set a Prescription Drug User Fee Act (PDUFA) goal date of August 2, 2023. FDA pre-license inspection of remestemcel-L manufacturing conducted As part of its ongoing review of the BLA, FDA has now conducted the Pre-License Inspection (PLI) of the manufacturing...

NASHVILLE, Tenn., May 25, 2023 (GLOBE NEWSWIRE) — CapStar Financial Holdings, Inc. (“CapStar”) (NASDAQ: CSTR), the parent company of CapStar Bank, announced today that it has completed its $10 million share purchase authorization on May 25, 2023. Within this authorization, the Company purchased 692,000 shares for an average price of $14.42. Since February 1, 2022, the Company repurchased 1,348,000 or 6% of total common shares outstanding. Additionally, the board of directors authorized a new authorization to repurchase up to $20 million of the Company’s outstanding common stock. In the current operating environment, the Company intends to maintain above industry capital levels with target Tangible Common Equity to Tangible Assets and Common Equity Tier 1 capital ratios of 8.5% and 12.0% respectively. The repurchase authorization...

FREEHOLD, NJ, May 25, 2023 (GLOBE NEWSWIRE) — UMH Properties, Inc. (NYSE: UMH) (TASE: UMH) is pleased to announce that on May 21, 2023, Samuel A. Landy, President and Chief Executive Officer, received an Honorary Doctorate Degree of Business Administration from Curry College in Milton, Massachusetts. In addition, on May 21, 2023, Laurie Landy, Founding Director and Development Director of Special Strides, received an Honorary Doctorate Degree of Humane Letters from Curry College. UMH Properties, Inc., which was organized in 1968, is a public equity REIT that owns and operates 135 manufactured home communities with approximately 25,700 developed homesites. These communities are located in New Jersey, New York, Ohio, Pennsylvania, Tennessee, Indiana, Maryland, Michigan, Alabama, South Carolina and Georgia. UMH also has an ownership...